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ABSTRACT
Identification of SNPs potentially associated with di-isocyanate asthma using a
luciferase reporter assay
Wentao Jiang
Occupational Asthma (OA) is a common lung disorder that can be caused or
aggravated by exposures and conditions in the work places. Di-isocyanate asthma (DA)
is one type of OA. Despite years of research, there are no reliable markers to predict
risk or susceptibility for DA. Previous studies have identified 23 candidate single
nucleotide polymorphisms (SNPs) that are potentially associated with genes that are
related with DA. In this study, we tested the functional relevance of the 23 candidate
SNPs (mostly intronic) in several DA-related genes. We hypothesized that some of
these SNPs may affect the binding of relevant transcription factors, causing altered
expression of these genes. We inserted short DNA fragments (~30 bp) containing the
SNPs and long DNA fragments containing multiple SNPs into the pGL3-promoter
firefly luciferase reporter vector and transfected them into adenocarcinomas human
alveolar basal epithelial cells (A549 cell line). The expression levels of different SNP
constructs were measured by luciferase reporter assay. Our results showed that 3 SNPs
(rs11571537, rs2287231 and rs2446824) that are located in ATF3, TAR1 and CDH17
genes, respectively, had significant difference in luciferase activities between risk and
non-risk alleles (C vs. T for rs11571537, A vs. G for rs2287231, and T vs. C for
rs2446824). Our data indicate that the SNPs we found may affect the expression of
ATF3, TAR1 and CDH17 genes, which may play important roles in the development of
the DA.

Acknowledgements

Foremost, I would like to express my sincere gratitude to the chair of my
advisory committee Dr. Jianbo Yao, for the continuous support of my master study and
research, for his patience, motivation, encouragement, and immense knowledge. His
guidance helped me in all the time of research and writing of this thesis.
I acknowledge the support by my thesis committee members Dr. Daniel G.
Panaccione and Dr. Vagner A. Benedito for their enthusiasm on teaching and insightful
comments on my thesis. Certainly their suggestions have made me a better speaker,
writer and thinker.
I would like to thank my colleagues in the lab, Mingxiang and Prasanthi, for the
stimulating discussions, for the friendly lab environment, and for all the fun we have
had in the past year.
Last but not the least, I would like to thank my girlfriend and my parents, for
supporting me throughout my life. I wish I could show them just how much I love and
appreciate them.

iii

Dedication

To Mom and Dad

iv

Table of Contents
Introduction ............................................................................................................................. 1
Literature Review .................................................................................................................... 4
1.

Occupational Asthma .................................................................................................... 4
History and Definition..................................................................................................... 4
Epidemiology and Pathophysiology ............................................................................... 5
Diagnosis and Management ............................................................................................ 6

2.

SNPs and GWAS study ................................................................................................. 7
SNPs .................................................................................................................................. 7
GWAS ............................................................................................................................... 8
Genes relates with occupational asthma ...................................................................... 11

3.

Eukaryotic Transcription Regulation ...................................................................... 12
Relationship of Chromatin Structure to Transcription ............................................. 13
Activators and Repressors ............................................................................................ 14

4.

Luciferase Assay ......................................................................................................... 16

Objectives of the Study ......................................................................................................... 18
Material and Method ............................................................................................................ 19
Study participants .................................................................................. 错误!未定义书签。
SNPs fragment design and annealing ............................................................................... 19
PCR amplification .............................................................................................................. 19
Gel purification, TA cloning, and double digestion .......................................................... 20
Cloning of expression reporter constructs ......................................................................... 22
Cell Culture and Transfection ........................................................................................... 23
Luciferase Assay ................................................................................................................. 24
Statistics analysis ................................................................................................................ 24
Results..................................................................................................................................... 26
Cloning of the reporter assay construct ............................................................................. 26
Quantitative analysis of Luciferase assay.......................................................................... 27
v

Discussion ............................................................................................................................... 29
Tables and Figures ................................................................................................................ 32
Reference ................................................................................................................................ 56

vi

List of Tables
Table 1. Top hits for SNPs associated with diisocyanate induced occupational
asthma (OA) from sequence data analysis ...................................................................... 33
Table 2. SNPs for which transcription factor binding sites have been identified in
cell lines .............................................................................................................................. 35
Table 3. Primers used in the study. .................................................................................. 36
Table 4. Detailed sequences of 23 SNPs fragment design .............................................. 38

vii

List of Figures
Figure 1. Bioluminescent reactions catalyzed by firefly and Renilla luciferases ......... 41
Figure 2. Example of a SNP fragment design ................................................................. 42
Figure 3. The pGL3-Promoter Vector circle map .......................................................... 43
Figure 4. Double digestion of CDH17-1469-OA11-2 and CDH17-1469-OA11-4 45
Figure 5. Cloning of the report assay constructs and Cloning PCR ............................. 44
Figure 6. Relative luciferase activities of SNPs that have significant differences
and CDH17-1469bp long fragments ........................................................................... 47
Figure 7. Relative luciferase activities of SNPs that have no significant difference .... 52

viii

Introduction

Occupational Asthma (OA) is one type of asthma that is work-related. It is the
most common lung disorder in many developed countries (Meyer et al., 1999 ；
Contreras, Rousseau and Chan-Yeung, 1994；Reijula and Patterson, 1994). This disease
can be caused or aggravated by exposures and conditions in the workplaces. OA has
two main types: immunologic and non-immunologic. It can be differentiated by the
appearance after a latency period. Di-isocyanate asthma (DA) is one type of
immunological asthma caused by isocyanate chemicals. Di-isocyanate chemicals are a
family of chemical building blocks mainly used to make polyurethane products.
Toluene di-isocyanate (TDI) and methylene diphenyl di-isocyanate (MDI) are the main
di-isocyanates. TDI is used in the production of flexible foams. MDI is used in the
production of a variety of polyurethane products like elastomers, sealants, adhesives,
and coatings (McDonald, 2000). The isocyanates have become the most common agent
causing OA, and nearly 10 percent OA cases are due to the isocyanate chemicals (ChanYeung and Malo, 1995).
SNPs are the most common form of genomic variations. They occur once every
several hundred base pairs throughout the human genome. The vast majority of SNPs
are neutral allelic variants. However, the few that do influence a phenotype in a
measurable way are important for understanding the underlying genetics of human
health. SNPs can be divided into three types. They may fall within coding sequences of
genes, non-coding regions of genes, or in the intergenic regions. Synonymous and
1

nonsynonymous SNPs are SNPs in the coding region. Synonymous SNPs do not affect
the protein sequence while nonsynonymous SNPs change the sequence of the protein.
SNPs that are not in protein-coding regions are called eSNPs (expression SNPs). They
may still affect gene splicing, transcription factor binding, messenger RNA degradation,
or the sequence of non-coding RNA (Katkoori, 2008).
Several genes, as well as environmental factors, have shown interactions with
OA (Mapp, 2003). OA is a good model for investigating the gene-environment
interactions (Park and Frew, 2002). To find the gene interaction with a specific disease,
linkage analysis is the way for identifying genetic regions which may cause disease.
Using candidate loci linkage disequilibrium mapping, finding single nucleotide
polymorphisms (SNPs) on suspicious genes might be helpful to understand
mechanisms of asthma (Palmer and Cookson, 2001). A preliminary study recruited
workers with occupational asthma caused by di-isocyanates at occupational health
clinics in Canada and Spain. The next-generation sequencing was performed in 91
workers with confirmed DA (cases) and compared to 293 subjects with sequencing data
from the 1,000 genomic (1KG) control data set and 143 significant SNPs associated
with DA were found (Lummus et al., 2017).
In this study, we examined top-ranked 23 SNPs from the preliminary study
(Table 1) to evaluate their effort on gene expression. We hypothesized these SNPs may
contain potential transcriptional elements that may affect transcriptional factor binding,
thus affecting gene expression. The candidate genes are known to have strong
relationships with di-isocyanates induced occupational asthma (Table 2). The main
2

purpose of this study was to identify SNPs that may affect the expression level of these
genes using a luciferase reporter assay.

3

Literature Review

1. Occupational Asthma

History and Definition
Occupational asthma (OA) is a common lung disorder. It is one of the most
common occupational lung diseases in many industrialized countries (Meredith and
Nordman, 1996). OA is worth to study because it has the potential to provide the
information about the effect of genetic, environmental and behavioral interactions in
onset of asthma (Maestrelli, 2004). Although OA was recognized in the early 18th
century, the definition of OA has met with difficulty until more recently. From textbook,
it briefly defines: occupational asthma is a disease characterized by variable airflow
limitation and/or airway hyperresponsiveness due to causes and conditions attributable
to a particular occupational environment and not to stimuli encountered outside the
workplace (Chan-Yeung, 1995). There are two types of OA; they are differentiated by
the appearance after a latency period-immunologic and nonimmunologic. Immunologic
OA appears after a variable period of worker exposure in causal agent and acquires
immunologically mediated sensitization. Immunologic asthma can be classified into
that caused by high-molecular or low-molecular-weight compounds. The highmolecular-weight (>5000 DA) compounds are an animal and plant proteins or
polysaccharides such as wheat flour and animal dander that cause an Immunoglobulin
E (IgE)-dependent immune response. The low-molecular-weight (<5,000 DA)
4

compounds are chemicals such as di-isocyanates and western red cedar that can also
initiate an immune response after repeated inhalation. While non-immunologic OA
appears without a latent period, it happens after exposure to high concentration of
workplace irritant. This reaction also called Irritant-induced asthma clinically (Bardana,
1999) (Tarlo and Broder, 1989). The airway dysfunction syndrome (RADS) is typical
irritant-induced asthma, which may occur after a single exposure to high levels of an
irritating vapor, fume, or smoke (Brooks, Weiss and Bernstein, 1985).

Epidemiology and Pathophysiology
In recent years, many large population-based studies of OA and information on
the occupation have been carried out. Such investigations point the risk of OA and
contribute to studies of OA. OA accounted for 26% of all work-related respiratory
disease reported to the Surveillance of Work and Occupational Respiratory Disease
(SWORD) program in the UK (Bakerly et al., 2008). In the United States, the analysis
of 1978 social security disability data point around 15% of asthma is attributed to
workplace exposure (Blanc, 1987). Moreover, six communities in Canada showed the
frequency of possible OA was as high as 36.1% (Allen, 2002).
Inhaled agents (High-molecular-weight or Low-molecular-weight) in a
workplace environment could lead to asthma by sensitization, normally, by creating
airway inflammation or by irritant reflex pathways. Until now, more than 250 agents
have been defined as causing immunologic OA (Chan-Yeung and Malo, 1994). The
pathophysiology of immunologic OA can be divided as IgE-Dependent and IgE
5

Independent. Most high-molecular-weight agents such as flour and animal or plant
protein induce asthma by producing IgE antibodies. Some specific low-molecularweights agents such as platinum salts and acid anhydrides also induce IgE antibodies,
may acting as haptens, working with body protein to form functional antigens (Baur
and Czuppon, 1995) (Biagini et al., 1985). The unique IgE antibodies on the surface of
different types of cells (Mast cell, Eosinophil, Macrophage, Neutrophil, dendritic cell,
etc.) combine with allergens giving rise to a cascade of events which result in cell
inflammation or form inflammatory mediators causing inflammation reaction. Other
low-molecular-weight agents such as isocyanates and plicatic acid can cause OA
without consistently induce IgE antibodies, the pathophysiology is still unclear (Sastre,
Vandenplas and Park, 2003). The mechanism of RADS is unknown. It has a postulation
that extensive denudation of the epithelium results in airway inflammation (Leroyer et
al., 1998).

Diagnosis and Management
The diagnosis of OA has to establish a relation between asthma and work (Anees,
2003) (Moscato, Malo and Bernstein, 2003). It should be based on a compatible history
and the presence of variable airflow limitation and lung volume. Making diagnosis need
the presence of both intermittent respiratory symptoms such as cough, chest tightness,
wheezing and physiologic evidence of reversible airways obstruction or
hyperresponsiveness. A non-specific bronchial hyperreactivity test is one way be used
to help diagnose occupational asthma. The IgE test is performed to evaluate whether
6

the subject is allergic to specific substances (de Groene et al., 2012). A spirometer also
can use to measure timed expired and inspired volumes can help to diagnose
occupational asthma. It is important to realize that no single test can diagnosis OA. The
best way to manage OA is the removal of the worker from further exposure and making
a substituted environment. If the substitution is not possible, changing the ventilation
system in the workplace or ongoing maintenance of engineering control are necessary.
Anti-inflammatory agents like corticosteroids, LKTRA or mast cell stabilizers can be
used depending on the severity of the case.

2. SNPs and GWAS study

SNPs
Single-nucleotide polymorphism (SNP) is a variation in a single nucleotide of
a DNA sequence at a specific position. It is occurring when a single nucleotide in the
genome or other shared sequence differs between members of a species or paired
chromosomes in an individual. The nucleotides change from purine to purine called
transition and from purine to pyrimidine called transversion. For example, two DNA
sequence fragments from different individuals, ACAGCTA to ACACCTA, contain one
single nucleotide difference. Most common SNPs have two alleles. In this case, there
are two alleles: G and C. There is always different frequency between two alleles, the
one with lower frequency at a locus in a specific position called minor allele, while the
one with a higher frequency called major allele. Single nucleotides can be changed
7

(substitution), removed (deletions) or added (insertion) to a polynucleotide sequence.
SNPs may be located on the coding, non-coding or intergenic region. Even if SNPs
locate on the coding region, it does not mean amino acid sequence change. This type of
SNPs can encode the same amino acid sequence, amking it a synonymous SNP. If a
different amino acid is produced, the SNPs is termed nonsynonymous. SNPs may also
generate stop codons, in this case, they are termed nonsense. SNPs that do not locate in
protein-coding regions may still have consequences for gene splicing, transcription
factor binding, or the sequence of non-coding RNA. SNPs occur once in every 300
nucleotides on average, which means there are nearly 10 million SNPs in the human
genome. Normally, these variations are found in the DNA between genes. They can act
as molecular markers, helping scientists locate genes that are associated with the disease.
When SNPs occur within a gene or in a regulatory region near a gene, they may play a
more direct role in disease by affecting the gene’s function.

GWAS
For years, researchers have tried to use genetic markers to identify genetic risk
factors for common and complex human disease. Genome-wide association study
(GWAS) is a powerful tool for the examination of a genome-wide set of genetic variants
in different individuals to see if any variant is associated with a phenotype or trait. The
ultimate goal of GWAS study is to use genetic risk factors to make predictions about
one individual is at risk and to identify the biological cornerstone of disease
susceptibility for developing prevention even treatment strategies (Bush and Moore,
8

2012). SNPs are ideal markers for GWAS study, because SNPs are notably a type of
common genetic variation; it is easy to find a relation between genotype and phenotype.
How to capture common variation? There is a hypothesis named common
disease/ common variant (CD/CV) that states common disorders are likely influenced
by genetic variation that is also common in the population (Bush and Moore, 2012).
Over a five-year test of this CD/CV hypothesis, for most of the common diseases, this
hypothesis is true. Based on this hypothesis, a project named Human Haplotype Map
(HapMap) builds a systematic approach to interrogate the common variation in the
human genome; the project included 11 human population with genotypes of 1.6
million SNPs (Altshuler et al., 2010). Because of the HapMap genotype data, the
examination of linkage disequilibrium (LD) is available. LD is a property of SNPs on
a stretch of genomic sequence that describes the degree to which an allele of one SNP
is inherited or correlated with an allele of another SNP, or even more than two SNPs
within a population. There are two common approaches to measuring LD: D’ and r2;
the equations is showing below:
𝑃

𝑃

−𝑃𝐴𝑏 𝑃𝑎𝐵

𝐴𝐵 𝑎𝑏
D’={ min(𝑃
𝑃

𝐴 𝑏 ,𝑃𝑎 𝑃𝐵 )

{

𝑖𝑓𝑃𝐴𝐵 𝑃𝑎𝑏 − 𝑃𝐴𝑏 𝑃𝑎𝐵 > 0}

𝑃𝐴𝐵 𝑃𝑎𝑏 − 𝑃𝐴𝑏 𝑃𝑎𝐵
𝑖𝑓𝑃𝐴𝐵 𝑃𝑎𝑏 − 𝑃𝐴𝑏 𝑃𝑎𝐵 < 0}
min(𝑃𝐴 𝑃𝐵 , 𝑃𝑎 𝑃𝑏 )

(𝑃𝐴𝐵 𝑃𝑎𝑏 −𝑃𝐴𝑏 𝑃𝑎𝐵 )2

𝑟 2=

𝑃𝐴 𝑃𝐵 𝑃𝑎 𝑃𝑏
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P represents the frequency, if r2 is high, it means two or more SNPs convey similar
information and only one of SNPs needs to be genotyped to capture the allelic variation.
LD can prevent genotyping SNPs provide redundant information.
Combining all the information from HapMap and LD analysis, and other details
such as indirect association, the chip-based microarray technology makes possible
assaying one million or more SNPs for GWAS research. The two most famous
platforms for GWAS are Illumina (San Diego, CA) and Affymetrix (Santa Clara, CA).
However, it is important to note that the genomic variation measurement changing
rapidly, more secrets of human disease phenotype will find its linking line with
genotype.
The primary approach of GWAS is the case-control setup. It compares two
large groups of individuals, one healthy control group and one case group with the
disease. All individuals in each group are genotyped for the majority of common known
SNPs. If the allele frequency is significantly different between the case and the control,
the SNPs then need to do more investigations. In such setups, the odds ratio will show
the effect size. The odds of disease for individuals having a specific allele and the odds
of disease for individuals who do not have that same allele divide together. The odds
ratio is higher than one if the allele frequency in the case group is much higher than in
the control group, and vice versa. Additionally, a P-value for the significance of the
odds ratio is typically calculated using a simple chi-squared test. Finding odds ratios
that are significant is prove of the SNPs is associated with the disease.

10

From the development of GWAS, we can tell this study has a huge impact on
the field of human genetics and the knowledge of the common human disease. In the
future, large data management system and cheap sequencing technologies will help
GWAS go up to a higher level.

Genes related to occupational asthma
Genetic factors that relate with occupational asthma have begun to be explored
for a long time (Mapp et al., 1994). Understanding the interaction between genetic
factors and the environment is the best way to characterize OA. The first pool or gene
family found associated with OA is major histocompatibility complex genes on
chromosome 6p. It encodes the HLA class II molecules that requires binding of antigen
to a T-cell receptor to start a series cascade reaction for antibody response. The major
histocompatibility complex class II proteins are the important factors for the specific
response to occupational agent, such as di-isocyanates, acid anhydrides, natural rubber
latex, western red cedar and animal proteins (Horne et al., 2000) (Rihs et al., 2002) (Jeal
et al., 2003). One research study indicates that about 40% of OA in the population
examined could be attributed to an HLA-DRβ1*07 phenotype (Jeal et al., 2003). In
general, HLA class II molecules provide evidence of a specific immunologic response
in asthma induced by low-molecular-weight reagents.
The second pool of genes is the superfamily of glutathione S-transferase (GST).
It comprises a family of eukaryotic and prokaryotic phase II metabolic isozymes best
known for their ability to catalyze the conjugation of the reduced form of glutathione
11

to xenobiotic substrates for the purpose of detoxification. This family mainly function
is protecting cells from oxidative stress products. One research indicates that patients
who exposed to TDI for 10 or more years have a lower frequency of the GSTP1 Val/Val
genotype compared to the subjects who had asthma. Data suggest that homozygosity
for the GSTP1*Val allele confers protection against TDI-induced asthma and airway
hyperresponsiveness (Mapp et al., 2002). Moreover, besides GST, N-acetyltransferase
genotypes can slow down acetylation genotypes posed a 7.77 fold greater risk of asthma,
especially TDI-induced asthma (Wikman et al., 2002). Because OA is not a simple
clinical disease but has to consider multiple factors, efforts should be made to use the
genetic information carefully.

3. Eukaryotic Transcription Regulation

Transcription regulation means the controls during the conversion from DNA to
RNA, thereby orchestrating gene activities. In a eukaryote, the phenotypic differences
that distinguish the many types of cells are majorly due to differences in the expression
of genes that code for proteins. The transcription processes play an important role in
the regulation of gene expression. Six potential control points during transcription by
RNA polymerase II are from the following series: activation of gene structure (open
chromatin), initiation and elongation, processing transcription, transport to the
cytoplasm from the nucleus, translation, degradation and turnover to mRNA.
Eukaryotes have three RNA polymerases: Pol I, Pol II, and Pol III. Each of these three
12

polymerases has specific targets and activities. They can work with each other or be
regulated by independent mechanisms. The mechanisms can be grouped into three areas:
(1) Gates for polymerases access to genes. This includes the functions of histone
remodeling enzymes, enhancers and repressors, transcription factors, and many other
complexes. (2) The engine of elongation. It can help to escape the promoter complex
and making a productive elongation. (3) The brake of transcription. Many factors can
control when and how termination occurs. All three of this system working accordingly
and making transcription accomplish successfully. Unlike prokaryotic system,
eukaryotes have a restrictive basal state which requires the recruitment of other factors.
This difference is largely due to the compaction of the eukaryotic genome by winding
DNA around histones to form higher order structures.

Relationship of Chromatin Structure to Transcription
In eukaryotes, the DNA is not “naked,” instead, it highly packed as chromatin
to fit in the nucleus. This process is accomplished by wrapping DNA on an octamer
structure protein called histone. The one single histone wrapped with 146 base pair of
DNA is nucleosome. It is basic units of chromatin. With these highly packed
characteristics, eukaryotes genes are at default status “silence.” To activate gene
expression, that is, initiation transcription, the chromatin structure should be opened.
The change of structure precedes the act of transcription and indicates that the gene can
be transcribed. Chromatin remodeling is the general process of inducing changes in
chromatin structure. It requires repositioning or displacing histones through recruiting
13

energy. There are several types of chromatin remodeling: (1) Histone slides along DNA.
This can alter rotationally and the translational position of the particular sequence on
the nucleosome. (2) The spacing may change between two octamer histones. (3) The
octamer histones may displace entirely thereby releasing “naked” DNA. The histone
structure has a pair of tails on the end of core histone, which can be modified by histone
acetyltransferases

(HATs),

histone

methyltransferases

(HMTs),

and

histone

deacetylases (HDACs), etc. These enzymes can add or remove covalent modifications
such as methyl groups, acetyl groups, phosphates, and ubiquitin. Usually, histone
acetylation is associated with transcription activation, and deacetylation is associated
with repression. As for methylation, generally, represents a feature of inactive
chromatin. However, some methylation also can activate transcription, such as di- or
tri-methylation of H3K4 is associated with transcriptional activation. Histone
phosphorylation also can affect chromatin structure, linking with transcriptional
repairing, chromosome condensation, and cell-cycle progression.

Activators and Repressors
The initiation of transcription requires a complicated protein-protein interaction
system that features transcription factors bound at enhancers with the basal apparatus
that assembles at the promotor including the RNA polymerase. The transcription factors
may stimulate transcription or delay transcription, the one with a positive effect called
activators, the one with a negative effect called repressors.
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Activators can be classified into three types by its function. The first class of activator
is true activator which contacts with basal apparatus at promotor either directly or
indirectly by co-activator. They all function on DNA or chromatin template. The second
class is the anti-repressor. It functions to unwind chromatin from closed status to open
status by recruiting the histone modifier enzymes or the chromatin remodeling
complexes. It can only function on chromatin template. The third class is architectural
proteins that can bend strand DNA and bring two or more functional areas together.
Regarding repressor, there are four possible illustrations of the mechanism. First, is
sequestering an activator in the cytoplasm, the repressor will mask activator pass
through the cytoplasm. The second one is repressor in nucleus masks activators which
have already bind on promotor. Third is repressor masking and holding in the cytoplasm
until it is released to enter the nucleus. The last one is competing with the enhancer.
In many cases, activators may not bind directly at the promotor area because
they lack a transcription activation domain. However, they can bind another protein that
has a transcription activation domain. An activation domain works by making proteinprotein interaction contacts with general transcription factors that promote assembly of
basal apparatus. Basal apparatus contains basal factor: TFIID, TFIIB, or TFIIA. All
components required for efficient transcription are basal apparatus, RNA polymerase,
activators, and co-activators. This component consists of ~40 proteins. They will
combine to form a big complex.

15

4. Luciferase Assay

Luciferase is a class of oxidative enzymes that produce bioluminescence. Using
this characteristic, researchers found a powerful and adaptable tools for cell biology
research-luciferase assay. It is commonly using on eukaryotic gene expression at
transcription level due to its convenience, relatively inexpensive and instantaneously
quantitative measurement. Luciferase assay technology can be applied to many areas.
It is important to find optic-reporter genes for the research of gene expression
and cellular events during the gene expression. Typically, a reporter gene should be
cloned with a DNA sequence of interest into an expression vector thereby transfect to
the specific cells. A good reporter gene is easy to be identified and can be measured
quantitatively. For a long time finding of bioluminescence, the luciferase from firefly
(Photinus Pyralis) and renilla (Renilla reniform) are well known in detail and
commonly using for dual-reporter assays. The reason to use dual-reporter assay is to
improve experimental accuracy. The “dual reporter” represents two individual reporter
enzymes within a single system measured and expressed simultaneously. Because
typically the experimental condition should be the same, the co-transfection of two
enzymes can act as an internal control and serve a baseline response. Normalizing the
activity of the experimental reporter to the activity of the internal control minimizes
16

experimental variability caused by differences in cell viability or transfection efficiency.
Through the dual reporter system, the external influence of experiment can be largely
removed. Also, because of the difference between Firefly and Renilla luciferases
enzyme structures and substrates requirements, makes it possible to selectively
discriminate between their bioluminescence reactions. Firefly luciferase is a 61 kDa
monomeric protein, and Renilla luciferase is a 36 kDa monomeric protein. They both
do not require post-translational processing for enzymatic activities (Wood et al., 1984)
(de Wet et al., 1985). Thus, they can function as a reporter immediately. The reactions
of both Firefly and Renilla luciferase show in Figure 1.
Luciferase assay has been developed for many research applications. The most
common application of luciferase assay is analyzing the function of cis-acting genetic
elements, especially promoters. Deletion or mutation will be made on promoter regions
and then measured by luciferase assay. For example, the human factor VIII gene
promoter region was found through luciferase assay, which contains around 200bp
(Figueiredo and Brownlee, 1995). The second application is focused on SNPs
researches. Through comparing two different allele luciferase activities, the functional
allele can be recognized. The real power of luciferase technology comes from its ability
to be used as cellular readouts for virtually any signaling event. By coupling a response
element controlled by the signaling event of interest to luciferase, researchers can point
the intracellular events due to quantified analysis. Luciferase assay can also help
research of RNA interference (RNAi). Once the reporter assay cell line established, the
signaling pathway of specific molecules can be detected.
17

Those applications mentioned before are just a few of the broad range of
luciferase assay application. It is clear that the luciferase assay is a powerful and
versatile tool for gene expression studies as well as studies of other cellular components
and events.

Objectives of the Study
A next-generation DNA sequencing analysis of di-isocyanate asthma cases
compared to control was made by a preliminary study. Twenty-three out of one
hundreds and forty-three SNPs were identified for further study. The SNPs are
contained in seven loci: CDH17 (10), ATF3 (6), FAM71A (2), PITPNC1, TACR1,
ZBTB16, LOC101929565. Based on the locations of the 23 SNPs, many of them are
located near each other. So we also designed two haplotypes long fragments containing
those linked SNPs as two new samples. In total, we have twenty-three SNPs and two
long fragments that contain several SNPs for this study. We hypothesized that some of
those risk SNPs will affect the binding of the relevant transcription factors which may
cause the expression changes of DA-related genes. The specific goal is to determine if
any of the risk SNPs are located in putative transcriptional elements that may affect the
binding of the relevant transcription factors which may change expression of genes
related to di-isocyanate induced occupation asthma using luciferase reporter assay.

18

Material and Method

SNP fragment design and annealing
Forty-six pairs of DNA oligonucleotides were designed and ordered from oligo
making company (Integrated DNA Technologies, Inc. IA) according to twenty-three
SNPs show on Table 1. For each SNP, two pairs of oligonucleotides around 25
nanomole DNA oligonucleotides having XhoI and KpnI restriction sites that contain
risk allele or non-risk allele were designed, an example of fragment design is shown in
Figure 2. Each oligo was spun down by mini centrifuge for 1 minute and diluted to 100
nM with molecular biology grade water. Forty-six pairs of oligonucleotides then were
incubated at 4℃ for one hour. For oligonucleotides annealing, each pair of
oligonucleotides were added 10 ul into PCR tube separately. PCR tubes later were
incubated in a PCR machine at 95℃ for 5 minutes and then cooled down to room
temperature (25℃) over 45 minutes. All tubes were kept in 4℃ fridges for storage until
use. Table 4 lists all 23 SNP insert sequences.

PCR amplification and gel purification
The long DNA region contains 8 different SNPs (rs2513787:8:94114852,
rs2446824:8:94115346,
rs2513788:8:94115668,

rs2446823:8:94115384,
rs2513789:8:94115885,

rs149630836:8:94115608,
rs2513790:8:94115919,

rs2446821:8:94116251) that are in linkage disequilibrium and located in 5’ end of the
CDH17 gene was amplified by PCR. The primers were designed according to the
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human genome. The DNA sample of an OA patient with heterozygotes was selected as
PCR template. PCR amplification was carried out with the reaction mixture composed
of 1 µl of diluted DNA sample of OA patient, 2.5 µl of gene-specific forward primer (5
µM) and reverse primer (5 µM) (see Table 3 for the list of primer sequences), 1.5 µl of
MgCl2 (25 mM), 0.5 µl of dNTP (10 mM), 5 µl of 5x PCR buffer, and 0.25 µl of Go
Taq® DNA polymerase (5 u/µl, Promega) with the final volume adjusted to 25 µl with
ddH2O. Amplification was carried out in a thermal cycler with 5 minutes of
denaturation at 94°C, followed by 35 cycles of 30 seconds of denaturing at 94°C, 1
minute and 30 seconds of annealing at 59°C, 1 minute of extension at 72°C with a final
extension at 72°C for 10 minutes. A negative control was always included and the
amplified products were mixed with loading buffer and separated on a 1% agarose gel
and stained with 1:10,000 diluted RGB nucleic acid stain (Phenix). The gel that
contained PCR amplified products was cut by scalpel accordingly and purified by using
QIAquick® Gel Extraction Kit (QIAGEN, Valencia, CA) following the manufacturer’s
instructions. The purified products then were diluted by 30 ul ddH2O, and the
concentration was measured by NanoDrop™ 2000 Spectrophotometer.

TA cloning and double digestion
The pGEM®-T Easy Vector (Promega, Madison, WI, USA) was used as the
vector for cloning PCR amplified products. Insert and vector were incubated with 2X
Rapid Ligation Buffer and T4 ligase (Promega, 3 u/µl) overnight at 4°C. The
Escherichia coli competent cells (Novagen) (> 1.5 x 108 CFU/µg) were transformed
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with 1 µl of ligation mixture using a heat shock method involving incubation on ice for
5 minutes, followed by a heat shock for 30 seconds in a 42°C water bath, and then on
ice for another 2 minutes. The transformation mixture was plated on LB 1%
carbenicillin agar plates. Plates were incubated overnight at 37°C. Four clones were
selected and inoculated in 3 ml of LB broth with 1% carbenicillin overnight in shaking
incubator at 37°C with 250 rpm. Plasmids were isolated from the overnight grown
culture using a QIAprep miniprep plasmid isolation kit (QIAGEN, Valencia, CA)
following the manufacturer’s instruction. The isolation products later were sent to DNA
sequencing with T7 and SP6 primers. The double digestion performed by adding 2.5 ul
of each XhoI and KpnI enzyme. Five µl of restriction buffer 1.1 was used according to
the information from Double Digest Finder (www.neb.com). All the enzymes, buffer
1.1 and 2.5 µg of the TA cloning sample was added into 1.5 ml Eppendorf tube with the
final volume adjusted to 50 µl with ddH2O (For each of TA cloning sample). The tubes
later were sent to 37℃ incubators for 3 hours. After 3 hours incubation, the digestion
samples were added with loading buffer and separated on a 1% agarose gel and stained
with 1:10,000 diluted RGB nucleic acid stain (Phenix). The double digestion result was
observed by comparing 1kb ladder (NEB, Ipswich, MA, USA). The restriction products
again were purified by using QIAquick® Gel Extraction Kit (QIAGEN, Valencia, CA)
following the instruction. The resulting sample was finally stored at 4℃.
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Cloning of expression reporter constructs
The pGL3-promoter Firefly Luciferase reporter vector (Promega, Madison, WI,
USA) was selected as the final reporter assay vector through comparing with other
similar reporter vectors. The detailed information of pGL3-promoter Firefly Luciferase
reporter vector is shown in Figure 3. Then, 0.25 µg of pGL3 reporter vector was
digested by 2.5 µl of each XhoI and KpnI enzyme and 5 µl of restriction buffer 1.1 into
the total volume adjusted to 50 µl with ddH2O and then kept into 37℃ incubators for 3
hours. The product was added with loading buffer and separated on a 1% agarose gel
and stained with 1:10,000 diluted RGB nucleic acid stain (Phenix). All the SNPs
fragments and the PCR amplified product were used as inserts for cloning. The ligations
were made with 3:1 molar ratio for the insert ratio to the vector. Two µl of T4 DNA
Ligase Buffer (10X) (Promega) was used to each of reactions and 1 µl of T4 ligase
(Promega, three u/µl) was added at the last steps of reaction with the final volume
adjusted to 20 µl for each of reactions. All the cloning samples were incubated in 4℃
overnight. Escherichia coli competent cells (Novagen) (> 1.5 x 108 CFU/µg) were
transformed with 1 µl of ligation mixture using a heat shock method involving
incubation on ice for 30 minutes, followed by a heat shock for 30 seconds in a 42°C
water bath, and then on ice for another 2 minutes. The transformation mixture was
plated on LB 1% carbenicillin agar plates. Plates were incubated overnight at 37°C.
Eight clones of each plate were selected and restricted on LB 1% carbenicillin agar
plates for inoculation after PCR checking. Simultaneously, eight clones of each plate
also were used as a template for cloning PCR to check if cloning were a success or not.
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For cloning PCR, forward primers were all forward oligonucleotides of each SNPs,
reverse primer was designed as a universal primer that located at the shared sequence
of pGL3 reporter vector. Each pair of primers were specifically generated a short
fragment around 205 bp for the 23 SNPs and 1496 bp for long fragments if the ligations
were succeeded. PCR amplification was carried out in a thermal cycler with 5 minutes
of denaturation at 94°C, followed by 35 cycles of 30 seconds of denaturing at 94°C, 1
minute and 30 seconds of annealing at 59°C, 1 minute of extension at 72°C with a final
extension at 72°C for 10 minutes. Figure 4 shows some examples of how plates were
designed as eight pieces for eight clones and the cloning PCR results on 1% agarose
gel. The verified clones were inoculated the next day and cultured in 3 ml of LB broth
with 1% carbenicillin overnight in shaking incubator at 37°C with 250 rpm. Plasmids
were isolated from the overnight grown culture using a QIAprep miniprep plasmid
isolation kit (QIAGEN, Valencia, CA) and QIAfilter plasmid midi kit (QIAGEN,
Valencia, CA) following manufacturer’s instructions. The plasmids isolated with the
mini kit were then sent to DNA sequencing.

Cell Culture and Transfection
A549 cells were cultured in DMEM–Dulbecco's Modified Eagle Medium
(Promega, Madison, WI, USA), supplemented with 10% fetal calf serum (Life
Technologies). A549 cells were digested by trypsin for 5 minutes at 37℃ when it
covered plate surface nearly 100%. Then A549 cells were plated in 96 well plates one
day before transfection. The amount of each cell in each well was adjusted according
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to transfection protocol. Transfections was carried out with Lipofectamine® LTX
Reagent (Invitrogen, CA). Each of the Pgl3-Promoter Vector containing the each
specific SNP (180 ng) was co-transfected with 20 ng of pRL Renilla Luciferase Control
Reporter Vectors pRL-CMV, (Promega, Madison, WI, USA). All the processes of cell
culture and transfection were conducted under sterile condition.

Luciferase Assay
Luciferase activity was measured using the Dual-Luciferase Assay System
(Promega, Madison, WI) following the manufacturer’s instructions. Briefly, after
transfection, cells were incubated at 37 °C in a CO2 incubator for 48 hours. Cells were
then lysed in the buffer provided by the manufacturer and mixed on a shaker for 15 min
at room temperature. The firefly and renilla luciferase activities of the cell lysates were
measured separately on a Synergy HT 96 microplate luminometer (Biotech, Winooski,
Vermont, USA).

Statistics analysis
All experiments were performed at least three times. To normalize luciferase
activities, the renilla luciferase activities were measured as normalization reference.
Shapiro-Wilk W test was made to make sure that the residuals of expression data are
normally distributed across their treatment means at α=0.05. Comparisons were
performed using Fisher’s least significant difference (LSD) test following one-way
analysis of variance (ANOVA) for the different groups. We also did Benjamini24

Hochberg adjustment (Q=0.1) for all the normalized data in order to control the false
discovery rate. Results are expressed as means ±S.D.
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Results
Cloning of haplotypes of CDH17-1469bp long fragments
The DNA sample of an OA heterozygous patient was used as a template for
PCR amplification of the CDH17-1469 bp long fragments. The primers were designed
to flank the two sides of the target region. The sequences of primers are shown in Table
3. The size of PCR product was around 1500 bp indicating that the PCR worked. The
PCR product was purified and used as the insert for TA cloning. Because the
amplification of the CDH17-1469 bp fragment was based on a heterozygous template,
two different haplotypes were expected. To identify two different haplotypes, plasmids
from four colonies were isolated for DNA sequencing. The two different haplotypes of
CDH17-1469bp were verified by sequencing analysis (CDH17-1469-OA11-2: C allele
for rs2513787 and G for rs2446821; CDH17-1469-OA11-4: An allele for rs2513787
and T for rs2446821). For further reporter assay construct cloning, the sticky restriction
sites of two haplotypes CDH17-1469-bp long fragments were made through double
digestion (Figure 4).

Cloning of the reporter assay construct
The 23 SNP short fragments and two haplotypes CDH17-1469-bp long
fragments were cloned into the pGL3-promoter Firefly Luciferase reporter vector
(Figure 5A). To ensure cloning success before plasmid isolation, colony PCR for each
fragment was performed. An example of colony PCR result is shown in Figure 5B
(Other 46 samples were also made); the CDH17-1469-bp long fragments colony PCR
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result is shown in Figure 5C. The expected band sizes of PCR products means cloning
of the reporter assay construct was successful. Isolations of all plasmids were made and
sent for DNA sequencing. All the sequences of clones prepared in pGL3-promoter
Firefly Luciferase reporter vector were confirmed by DNA sequencing.

Quantitative analysis of Luciferase assay
The A549 cell line was cultured in DMEM with fragments transfection. The 23
short fragments and the two haplotypes of the CDH17-1469-bp long fragments were
transfected with the pRL renilla luciferase control reporter vectors into the A549 cell
line. The luciferase activities were measured 48 hours after transfection. Statistical
analyses were used according to normalized data: 23 SNPs normalized luciferase
activity values indicated each SNP normalized luciferase activity data was normally
distributed through the Shapiro-Wilk W test with treatment means at a α=0.05. CDH171469-OA11 long fragments normalized luciferase activity values also were normally
distributed. With normally distributed data points, an one-way analysis of variance
(ANOVA) is appropriate.

SNPs associated with di-isocyanate asthma
To determine if any SNP affected transcription factor binding, we used Fisher’s
least significant difference (LSD) test following by one-way analysis of variance
(ANOVA) and Benjamini-Hochberg adjustment (Q=0.1) for all the normalized data.
We found 3 SNPs out of 23 SNPs (T vs. C for rs11571537, A vs. G for rs2287231, and
A vs. G for rs2446824) have significant difference in normalized luciferase activities
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between risk and non-risk alleles (*p < 0.025, *p < 0.01, *p < 0.01), as Figure 6A,
Figure 6B and Figure 6C show respectively. The two haplotypes of CDH17-1469-OA11
showed no significant difference between each other, but both haplotypes showed
significant difference expression level (*p < 0.01) compare to the pGL-3-promoter
control group

(Figure 6D). We were unable to find any significant difference for the

rest of the 20 SNPs (Figure 7). These findings support the hypothesis that some SNPs
out of 23 SNPs are associated with di-isocyanate asthma.
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Discussion
Occupational asthma is an inflammatory disease caused by environmental and
genetic factors. Some studies identified and characterized the interaction between SNPs
and inflammatory disease (Kim et al., 2009) (Tokuhiro et al., 2003). Based on GWAS
research before, one hundred and forty-three SNPs were identified that show
association with DA, of which all but one SNP were located in intronic regions. From
transcriptomic analysis that used available transcription factor (TF) datasets from
relevant lung-derived tissues and cell lines, including ChIP-seq datasets for TFs,
regulatory histone markers, and DNase-seq (open chromatin), the top-ranked 23 SNPs
were identified based on the number of datasets they overlap and the biological
relevance of the associated SNPs (Lummus et al., 2017). Based on the locations of the
23 SNPs, many of them are located near to each other, so we also designed two
haplotypes long fragments containing those linked SNPs as two new samples. The
possible roles of these variants on gene expression and protein function are under
investigation in separate study. In this study, out of these 23 SNPs, we identified 3 SNPs
that may be considered as genetic factors related with DA.

The SNP rs2287231 is located upstream of the TAR1 gene. TAR1 was found in
mitochondria, coded within the 25S rRNA gene on the opposite strand. It may be
involved in mtDNA stability or mitochondrial gene expression regulation at the post-
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transcriptional level (Coelho, 2002). It seems like TAR1 gene has no interaction with
OA. Nevertheless, the TAR1 protein may interact with other proteins as a co-activator.

The SNP rs2446824 is located downstream of CDH17 gene. This gene belongs
to the cadherin superfamily that encodes calcium-dependent, membrane-associated
glycoproteins. In human, CDH17 gene encodes cadherin 17 protein, which is a
component of the gastrointestinal tract and pancreatic ducts. This protein may play an
important role in the morphological organization of liver and intestine
(Ncbi.nlm.nih.gov, 2017). Perhaps the shape of pancreatic ducts has some influence on
OA. A GWAS study also indicated that SNP (rs2514805) near the CDH17 genes on
chromosome 8 has a significant association with DA (Yucesoy et al., 2015). This
evidence suggests CDH17 gene expression may be affected by SNPs near the CDH17
gene. Although both SNP rs2287231 and SNP rs2446824 are not located on promoter
regions, transcription regulation is not a simple process of binding transcription factors
with promotor. The recruitment of proteins that contain different function is a critical
step for a successful transcription. Therefore, SNPs around a gene may also affect the
regulation of gene expression.

The SNP rs11571537 locates on the first intron of activating transcription factor
3 (ATF3) gene. ATF3 is a member of the ATF/cyclic AMP response element-binding
family of a transcription factor. The ATF family represents a large group of basicregion leucine zipper (bZIP) transcription factors. The common feature of the ATF
family is they all can use bZIP to form homodimers or heterodimers with other bZIP
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that contains other proteins to recognize specific DNA binding in the basic region (Hai,
2006). Since ATF3 most times has to work with other proteins, it is hard to define it as
an activator or repressor (Hai et al., 1999). Studies point out negative feedback
regulation of ATF3 as the key to protect acute inflammatory syndromes through
limiting pro-inflammatory cytokine expression, and ATF is critical in the suppression
of inflammatory responses to infection and allergy (Whitmore et al., 2007). The most
remarkable research that connects with our study is in a mouse model of ovalbumin
allergen-induced asthma. ATF3 expression was shown to be significantly increased
(Gilchrist et al., 2008). From these data, it is clear that the ATF3 gene plays an important
role in the inflammatory disease. More specifically, it has a connection with OA. ATF3
acts like a switch for stimulating transcription processes by preventing the access of
inhibitory co-factors to gene promoter. It is possible that alternative splicing of the
ATF3 gene can be physiologically critical in the regulation of target genes.

In this study, we only studied the SNPs at the gene expression level without
protein expression level research. The magnitude of difference in transcriptional
processes cannot be defined. Based on these data, further research on DA can determine
if the identified risk SNPs are located in any putative transcription elements that may
affect the binding of the relevant transcription factors. The transcription element search
software [(TESS) http://www.cbil.upenn.edu/tess/] can analyze the promoter sequence
of this three genes, and the electrophoretic mobility shift assay (EMSA) can measure
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the capacity of any identified transcription elements to bind candidate transcription
factors and to investigate the influence of variations on transcription factor binding.

In addition, the long fragment CDH17-1469bp-OA11 that contains eight SNPs
is a test model that we may use for the future research. According to the description of
eukaryotic transcription regulation (Krebs et al., 2014), we believe the transcription of
a specific gene can be regulated by more than one SNP. A haplotype, more specifically,
probably decides the amount of gene expression more than just one SNP. Even these
two haplotypes in this study did not show a significant difference. The higher
expression than original pGL3-promoter reporter vector still indicates expression level
changed because of the participation of eight SNPs. The more groups of haplotypes will
be tested in the future.

In conclusion, our data indicate that these three SNPs (rs11571537, rs2287231,
and rs2446824) located inside of ATF3 gene, upstream of TAR1 gene and downstream
of CDH17 gene, respectively, cause a significant difference in luciferase activities
between risk and non-risk alleles (C vs. T for rs11571537, A vs. G for rs2287231, and
T vs. C for rs2446824) and may play important roles in the development of the DA.
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Tables and Figures
Table 1. Top ranked SNPs associated with di-isocyanate-induced occupational
asthma (OA) based on sequence data analysis
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Table 2. SNPs for which transcription factor binding sites have been identified
in cell lines
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Table 3. Primers used in the study.

PCR
method

Regular
PCR

Regular
PCR

Primer name

Primer sequences

1LOC-A-F

CCATCTGGTTAACCAAAGAGGGCTTCCAGGAGC

1LOC-G-F

CCATCTGGTTAACCAAGGAGGGCTTCCAGGAGC

2ATF3-A-F

CAGTGTGGAGCCTCTTACTGTCTTGTTCATTCC

2ATF3-T-F

CAGTGTGGAGCCTCTTTCTGTCTTGTTCATTCC

3ATF3-C-F

CACCACAGATCCCCGGCTGAGAGGAATGCCCAC

3ATF3-T-F

CACCACAGATCCCCGGTTGAGAGGAATGCCCAC

4ATF3-C-F

CTGTTTCATGTCTAAACGTGTGTCTCATTGTTC

4ATF3-T-F

CTGTTTCATGTCTAAATGTGTGTCTCATTGTTC

5ATF3-G-F

CTTGACCTCATGTATGGTTCCTTTAAATGATCC

5ATF3-T-F

CTTGACCTCATGTATGTTTCCTTTAAATGATCC

6ATF3-A-F

CAGCACTTCTTTCAGGAGATAATTTATGTTCCC

6ATF3-G-F

CAGCACTTCTTTCAGGGGATAATTTATGTTCCC

7ATF3-A-F

CTGATGTGTATGGTAAATGTAAATGAAGGTCTC

7ATF3-G-F

CTGATGTGTATGGTAAGTGTAAATGAAGGTCTC

8FAM71A-Del-F

CTCCCATTTAATCCTCACAACTGCTACCCCCC

8FAM71A-Ins-F

CTCCCATTTAATCCTCACAACAACTGCTACCCCCC

9FAM71A-A-F

CACACCACATGCCCAGATAGAGATGTACCTGTC

9FAM71A-G-F

CACACCACATGCCCAGGTAGAGATGTACCTGTC

10TACR1-A-F

CCACTTGGCTGATGAAAGACAACATTGGCAGGC

10TACR1-G-F

CCACTTGGCTGATGAAGGACAACATTGGCAGGC

11CDH17-A-F

CCATTTTTTCCATTGCAACATTTGGGCAGATGC

11CDH17-G-F

CCATTTTTTCCATTGCGACATTTGGGCAGATGC

12CDH17-A-F

CCAGAAGCAAAAGTTCATCTGACTGAGGGAAAC

12CDH17-C-F

CCAGAAGCAAAAGTTCCTCTGACTGAGGGAAAC

13CDH17-del-F

CGAATTGCCTACTATCTCAGTAGCCCACCATC

13CDH17-Ins-F

CGAATTGCCTACTATCTCAGTAGTCAGTAGCCCACCATC

14CDH17-G-F

CGCCCATCCTCCTTGTGTTATGGGCCCAGATGC

14CDH17-T-F

CGCCCATCCTCCTTGTTTTATGGGCCCAGATGC
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PCR
method

Primer name

Primer sequences

15CDH17-A-F

CTGTTTTTTCATTGTCAATGTTATCTAAGTCAC

15CDH17-G-F

CTGTTTTTTCATTGTCGATGTTATCTAAGTCAC

16CDH17-C-F

CTTCCAAGCACATACTCAAAAGAATCACTTGAC

16CDH17-T-F

CTTCCAAGCACATACTTAAAAGAATCACTTGAC

17CDH17-A-F

CGGTCCTCCTTCAGAAAAACATCAGCTTCCCAC

17CDH17-C-F

CGGTCCTCCTTCAGAACAACATCAGCTTCCCAC

18CDH17-A-F

CAGTCAGCTCAGGCCAACATAACAAAATACCAC

18CDH17-C-F

CAGTCAGCTCAGGCCACCATAACAAAATACCAC

19CDH17-A-F

CGAGAAACTCTTGGGAAACATCCAGAGTGAAGC

19CDH17-C-F

CGAGAAACTCTTGGGACACATCCAGAGTGAAGC

20CDH17-C-F

CAAGGAGCAAGTGGTGCTCTACGTGAACAGGTC

20CDH17-G-F

CAAGGAGCAAGTGGTGGTCTACGTGAACAGGTC

21ZBTB16-A-F

CCTTGTCATATGTAAAAAGGGAATCATTGTGGC

21ZBTB16-G-F

CCTTGTCATATGTAAAGAGGGAATCATTGTGGC

22PITPNC1-A-F

CAATCTCCCAGGTGGCATATTGCTAGAGGAGAC

22PITPNC1-G-F

CAATCTCCCAGGTGGCGTATTGCTAGAGGAGAC

23ATF3-del-F

CTCAGGAGGCTGAGGCAGAAGGATGGCTTGAC

23ATF3-Ins-F

CTCAGGAGGCTGAGGCAGAGAAGGATGGCTTGAC

pGL3-R280

TGGTGGCTTTACCAACAGTAC

pGL3-R364

CCTTATGCAGTTGCTCTCCAG

CDH17-1496-F

GTGGCAGCTTCTCATGTGAAC

CDH17-1496-R

TGGTATTTTGTTATGGTGGCCTG

CDH17-1496KpnI
CDH17-1496XhoI

GGCCGGTACCTTGTTGCAAGGATTCGGCGAC
CCGGCTCGAGCTGAGCTGACTGATACAGAATC
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Table 4. Sequence of oligos used for preparation of SNP fragments

SNP

1LOC

Variant

Design

1LOC-A

CCATCTGGTTAACCAAAGAGGGCTTCCAGGAGC

SNP

13CDH17

Variant

Design

CDH17-

CGAATTGCCTACTATCTCAGTAGCCCACCATC

Del
CATGGGTAGACCAATTGGTTTCTCCCGAAGGTCCTCGA

CATGGCTTAACGGATGATAGAGTCATCGGGTGGTAGAGCT

GCT
1LOC-G

CCATCTGGTTAACCAAGGAGGGCTTCCAGGAGC

CDH17-Ins
CGAATTGCCTACTATCTCAGTAGTCAGTAGCCCACCATC

CATGGGTAGACCAATTGGTTCCTCCCGAAGGTCCTCGA
GCT

CATGGCTTAACGGATGATAGAGTCATCAGTCATCGGGTGG
TAGAGC

2ATF3

2ATF3-A

CAGTGTGGAGCCTCTTACTGTCTTGTTCATTCC

14CDH17

14CDH17-

CGCCCATCCTCCTTGTGTTATGGGCCCAGATGC

G
CATGGTCACACCTCGGAGAATGACAGAACAAGTAAGG

CATGGCGGGTAGGAGGAACACAATACCCGGGTCTACGAG

AGCT

CT

2ATF3-T

CAGTGTGGAGCCTCTTTCTGTCTTGTTCATTCC

14CDH17-

CGCCCATCCTCCTTGTTTTATGGGCCCAGATGC

T

3ATF3

CATGGTCACACCTCGGAGAAAGACAGAACAAGTAAGG

CATGGCGGGTAGGAGGAACAAAATACCCGGGTCTACGAG

AGCT

CT

3ATF3-C

CACCACAGATCCCCGGCTGAGAGGAATGCCCAC

15CDH17

15CDH17-

CTGTTTTTTCATTGTCAATGTTATCTAAGTCAC

A
CATGGTGGTGTCTAGGGGCCGACTCTCCTTACGGGTGA

CATGGACAAAAAAGTAACAGTTACAATAGATTCAGTGAGC

GCT

T

3ATF3-T

CACCACAGATCCCCGGTTGAGAGGAATGCCCAC

15CDH17-

CTGTTTTTTCATTGTCGATGTTATCTAAGTCAC

G

4ATF3

CATGGTGGTGTCTAGGGGCCAACTCTCCTTACGGGTGA

CATGGACAAAAAAGTAACAGCTACAATAGATTCAGTGAGC

GCT

T

4ATF3-C

CTGTTTCATGTCTAAACGTGTGTCTCATTGTTC

16CDH17

16CDH17-

CTTCCAAGCACATACTCAAAAGAATCACTTGAC

C
CATGGACAAAGTACAGATTTGCACACAGAGTAACAAG

CATGGAAGGTTCGTGTATGAGTTTTCTTAGTGAACTGAGC

AGCT

T

4ATF3-T

CTGTTTCATGTCTAAATGTGTGTCTCATTGTTC

16CDH17-

CTTCCAAGCACATACTTAAAAGAATCACTTGAC

T
CATGGACAAAGTACAGATTTACACACAGAGTAACAAG

CATGGAAGGTTCGTGTATGAATTTTCTTAGTGAACTGAGCT

AGCT
5ATF3

5ATF3-G

CTTGACCTCATGTATGGTTCCTTTAAATGATCC

17CDH17

17CDH17-

CGGTCCTCCTTCAGAAAAACATCAGCTTCCCAC

A
CATGGAACTGGAGTACATACCAAGGAAATTTACTAGGA

CATGGCCAGGAGGAAGTCTTTTTGTAGTCGAAGGGTGAG

GCT

CT
CTTGACCTCATGTATGTTTCCTTTAAATGATCC

5ATF3-T

17CDH17-

CGGTCCTCCTTCAGAACAACATCAGCTTCCCAC

C
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6ATF3

CATGGAACTGGAGTACATACAAAGGAAATTTACTAGGA

CATGGCCAGGAGGAAGTCTTGTTGTAGTCGAAGGGTGAG

GCT

CT

6ATF3-A

CAGCACTTCTTTCAGGAGATAATTTATGTTCCC

18CDH17

18CDH17-

CAGTCAGCTCAGGCCAACATAACAAAATACCAC

A
CATGGTCGTGAAGAAAGTCCTCTATTAAATACAAGGGA

CATGGTCAGTCGAGTCCGGTTGTATTGTTTTATGGTGAGCT

GCT
6ATF3-G

CAGCACTTCTTTCAGGGGATAATTTATGTTCCC

18CDH17-

CAGTCAGCTCAGGCCACCATAACAAAATACCAC

C
CATGGTCGTGAAGAAAGTCCCCTATTAAATACAAGGGA

CATGGTCAGTCGAGTCCGGTGGTATTGTTTTATGGTGAGCT

GCT
7ATF3

7ATF3-A

CTGATGTGTATGGTAAATGTAAATGAAGGTCTC

19CDH17

19CDH17-

CGAGAAACTCTTGGGAAACATCCAGAGTGAAGC

A
CATGGACTACACATACCATTTACATTTACTTCCAGAGAG

CATGGCTCTTTGAGAACCCTTTGTAGGTCTCACTTCGAGC

CT

T
CTGATGTGTATGGTAAGTGTAAATGAAGGTCTC

19CDH17-

7ATF3-G

8FAM71

8FAM71

A

A-Del

C
CATGGACTACACATACCATTAACATTTACTTCCAGAGAG

CATGGCTCTTTGAGAACCCTGTGTAGGTCTCACTTCGAGC

CT

T
CTCCCATTTAATCCTCACAACTGCTACCCCCC

20CDH17

A

A-A

CAAGGAGCAAGTGGTGCTCTACGTGAACAGGTC

CATGGAGGGTAAATTAGGAGTGTTGACGATGGGGGGA

CATGGTTCCTCGTTCACCACGAGATGCACTTGTCCAGAGC

GCT

T
CTCCCATTTAATCCTCACAACAACTGCTACCCCCC

20CDH17-

A-Ins

9FAM71

20CDH17C

8FAM71

9FAM71

CGAGAAACTCTTGGGACACATCCAGAGTGAAGC

CAAGGAGCAAGTGGTGGTCTACGTGAACAGGTC

G
CATGGAGGGTAAATTAGGATGTGTGTTGACGATGGGGG

CATGGTTCCTCGTTCACCACCAGATGCACTTGTCCAGAGC

GAGCT

T

CACACCACATGCCCAGATAGAGATGTACCTGTC

21ZBTB1

21ZBTB16

6

-A

CATGGTGTGGTGTACGGGTCTATCTCTACATGGACAGA

CCTTGTCATATGTAAAAAGGGAATCATTGTGGC

CATGGGAACAGTATACATTTTTCCCTTAGTAACACCGAGCT

GCT
9FAM71

CACACCACATGCCCAGGTAGAGATGTACCTGTC

21ZBTB16

A-G

CCTTGTCATATGTAAAGAGGGAATCATTGTGGC

-G
CATGGTGTGGTGTACGGGTCCATCTCTACATGGACAGA

CATGGGAACAGTATACATTTCTCCCTTAGTAACACCGAGCT

GCT
10TACR

10TACR1

1

-A

CCACTTGGCTGATGAAAGACAACATTGGCAGGC

22PITPN

22PITPNC

C1

1-A

CATGGGTGAACCGACTACTTTCTGTTGTAACCGTCCGA

CAATCTCCCAGGTGGCATATTGCTAGAGGAGAC

CATGGTTAGAGGGTCCACCGTATAACGATCTCCTCTGAGCT

GCT
10TACR1

CCACTTGGCTGATGAAGGACAACATTGGCAGGC

22PITPNC

-G

11CDH1

11CDH17

7

-A

CAATCTCCCAGGTGGCGTATTGCTAGAGGAGAC

1-G
CATGGGTGAACCGACTACTTCCTGTTGTAACCGTCCGA

CATGGTTAGAGGGTCCACCGCATAACGATCTCCTCTGAGC

GCT

T
CCATTTTTTCCATTGCAACATTTGGGCAGATGC

23ATF3

23ATF3-

CTCAGGAGGCTGAGGCAGAAGGATGGCTTGAC

Del

39

CATGGGTAAAAAAGGTAACGTTGTAAACCCGTCTACGA

CATGGAGTCCTCCGACTCCGTCTTCCTACCGAACTGAGCT

GCT
11CDH17

CCATTTTTTCCATTGCGACATTTGGGCAGATGC

-G

12CDH1

12CDH17

7

-A

23ATF3-

CTCAGGAGGCTGAGGCAGAGAAGGATGGCTTGAC

Ins
CATGGGTAAAAAAGGTAACGCTGTAAACCCGTCTACG

CATGGAGTCCTCCGACTCCGTCTCTTCCTACCGAACTGAG

AGCT

CT

CCAGAAGCAAAAGTTCATCTGACTGAGGGAAAC

CATGGGTCTTCGTTTTCAAGTAGACTGACTCCCTTTGA
GCT
CCAGAAGCAAAAGTTCCTCTGACTGAGGGAAAC
12CDH17
-C

CATGGGTCTTCGTTTTCAAGGAGACTGACTCCCTTTGA
GCT
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Figure 1

Figure 1. Bioluminescent reactions catalyzed by firefly and Renilla luciferases.
Photon emission is achieved through oxidation of beetle luciferin in a reaction that
requires ATP, Mg2+, and O2. This assay chemistry generates a “flash” of light that
rapidly decays after the substrate and enzyme are mixed. The luminescent reaction
catalyzed by Renilla luciferase utilizes O2 and coelenterate luciferin. (Protocol of DualLuciferase reporter assay system)
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Figure 2

Figure 2. An example of an SNP fragment design. According to the information from
dbSNP of NCBI (https://www.ncbi.nlm.nih.gov/snp), the name, location, sequence and
detail information of an SNP are showed on top. The two restriction sites were added
at each end of two alleles with sticky ends. The blue parts are the two alleles of one
SNP. The yellow parts at each sequence ends are restriction sites; the yellow middle
parts are the SNP variant. The sequences followed by red parts are fragments that need
to order from the company.
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Figure 3

Figure 3. The pGL3-Promoter Vector circle map. The luc+ can encode the
modified firefly luciferase; Ampr, gene conferring ampicillin resistance in Escherichia
coli; f1 ori, origin of replication derived from filamentous phage; ori, origin of plasmid
replication in E. coli. Arrows within luc+ and the Ampr gene indicate the direction of
transcription; the arrow in f1 ori indicates the direction of ssDNA strand synthesis.
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Figure 4

Figure 4. Double digestion of CDH17-1469-OA11-2 and CDH17-1469-OA11-4. The
double digestion was analyzed on a 1% agarose gel. The two bands around 1500 bp
proved the CDH17-1469-OA11-2 and CDH17-1469-OA11-4 were digested
successfully from pGEM®-T Easy Vector and ready to be used as inserts.
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Figure 5

Figure 5. Cloning of the reporter constructs and colony PCR. A. Cloned luciferase
reporter constructs containing the SNPs. Gray boxes, the 3’UTR used in the reporter
constructs that contain the target SNPs or the long SNPs fragment. Red star
representsthe risk allele of each SNP that may affect expression level change. Red box,
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the long fragment that contains multiple SNPs, represented a haplotype. B. The colony
PCR amplification using eight different single colonies that possibly have cloned report
construct as templates showed single band around 250 bp, indicating that the cloning
of report constructs are of good quality and ready for DNA sequencing. All the 46
clones were tested before DNA sequencing. C. The colony PCR amplification using
eight different single colonies that possibly have cloned reporter construct as templates
showed single band around 1500 bp, indicating that the cloning of reporter constructs
are of good quality and ready for DNA sequencing.

46

Figure 6
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Figure 6. Normalized luciferase activities of SNPs and CDH17-1469 bp long
fragments. A. Normalized luciferase activities of SNP rs11571537 between risk and
non-risk alleles (C vs. T). Significant difference between two alleles was observed by
Fisher’s least significant difference test following one-way analysis of variance
(Difference [D], 0.2880018; 95% Confidence interval [CI], 0.038-0.540, p = .025). B.
Normalized luciferase activities of SNP rs2287231 between risk and non-risk alleles (A
vs. G). Significant difference between two alleles was observed by Fisher’s least
significant difference test following one-way analysis of variance (Difference [D],
0.4206311; 95% Confidence interval [CI], 0.088-0.752, p = .01). C. Normalized
luciferase activities of SNP rs2446824 between risk and non-risk alleles (T vs. C).
Significant difference between two alleles was observed by Fisher’s least significant
difference test following one-way analysis of variance (Difference [D], 0.2407542; 95%
Confidence interval [CI], 0.059-0.423, p = .01). D. Normalized luciferase activities
of CDH17-1496bp-OA11 between two haplotypes. No significant difference between
two haplotypes was observed by Fisher’s least significant difference test following oneway analysis of variance. Different letters indicate statistical difference (p<0.05).
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Figure 7. Relative luciferase activities of SNPs that have no significant difference.
Relative luciferase activities of all SNPs above were analyzed by student t-test. No
significant difference between each risk allele and non-risk allele was observed.
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